Axsome Therapeutics (0HKF) Price & Analysis

4 Followers

0HKF Stock Chart & Stats

$238.74

-$1.98(-0.82%)

At close: Jul 27 4:00 PM EDT

$238.74

-$1.98(-0.82%)

Day’s Range― - ―

52-Week Range$103.40 - $263.93

Previous CloseN/A

Volume138.00

Average Volume (3M)547.00

Market Cap

$11.22B

Enterprise Value$8.57K

Total Cash (Recent Filing)$305.11M

Total Debt (Recent Filing)$219.90M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Aug 10, 2026

EPS Estimate

-0.89

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.73

Shares Outstanding51,459,766

10 Day Avg. Volume250

30 Day Avg. Volume547

Financial Highlights & Ratios

PEG Ratio1.29

Price to Book (P/B)102.90

Price to Sales (P/S)14.23

P/FCF Ratio-96.78

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$300.38

Price Target Upside25.82% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-2.28

Revenue Forecast (FY)$971.90M

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Scale & High Gross MarginsSustained, rapid top-line expansion combined with ~91%–93% gross margins indicates strong product economics and scalable revenue per prescription. High gross margins provide room to invest in commercialization and R&D while enabling operating leverage as adoption and payer access deepen over months to years.

Regulatory Win & AUVELITY Commercial MomentumA first-in-class FDA approval materially expands AUVELITY's addressable market and durability of sales. Combined with growing scripts, expanding sales force and broad payer coverage, this structural change supports multi-year revenue potential and raises the likelihood of sustained commercial leadership in the indication.

Advancing Late-Stage Pipeline & NDA FilingsProgressing candidates to NDA submission and initiating multiple Phase III programs diversifies growth drivers beyond current products. Successful late-stage readouts could create new label expansions and indications, reducing single-product concentration risk and supporting multi-year revenue growth if approvals and commercialization succeed.

Bears Say

Ongoing Cash Burn & Negative Operating Cash FlowNegative operating and free cash flow means the business remains dependent on existing cash and potential external financing until sustained profitability. This structural cash burn raises execution risk for multi-stage commercialization and trials, making runway sensitive to slower uptake or higher spending.

Elevated Leverage And Thin Equity CushionHigh debt relative to a small equity base materially limits balance-sheet flexibility and increases refinancing risk if growth or cash generation falters. Elevated leverage constrains maneuverability on large investments, M&A, or extended commercialization pushes without dilutive or costly capital raises.

High Gross-to-Net Discounts And Elevated SG&ASustained high gross-to-net discounts materially reduce realized revenue per script even as reported sales grow, while elevated SG&A from national campaigns and sales expansion raises the break-even hurdle. Together these structural pressures can compress operating margins and lengthen time to cash-flow positivity.

Axsome Therapeutics News

These Are the Stocks Reporting Earnings Today – August 10, 2026

Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly...

2h ago

DJT

Axsome Therapeutics price target lowered to $306 from $310 at Mizuho

Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $306 from $310 and keeps an Outperform...

10d ago

AXSM

Shopify downgraded, Five Below upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

20d ago

Axsome Therapeutics initiated with an Outperform at BMO Capital

BMO Capital analyst Malcolm Hoffman initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price...

21d ago

AXSM

Axsome Therapeutics initiated with an Outperform at BMO Capital

BMO Capital initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price target Published first...

21d ago

AXSM

Axsome Therapeutics announces FDA acceptance of AXS-12 NDA

Axsome Therapeutics (AXSM) announced that the FDA has accepted for filing the company’s new drug application for AXS-12...

26d ago

AXSM

AXSM Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Axsome Therapeutics Inc. (AXSM) is scheduled to report 2nd quarter earnings on 08/10/2026, before the market opens. Regarding...

2d ago

AXSM

Axsome, Five Below, APPS, Intuit, Adobe Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($AXSM) ), ( ($FIVE) ), ( ($APPS) ), ( ($INTU)...

16d ago

ADBE

APPS

Axsome Advances AXS-14 Fibromyalgia Trial With New Long-Term Safety Update

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. The Phase 3 study “An Open-Label...

17d ago

AXSM

Axsome’s CLARITY Trial Targets Sleepy Depression: What Investors Should Watch

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Axsome Therapeutics, Inc. is running a...

17d ago

AXSM

Axsome’s Phase 3 Fibromyalgia Trial of AXS-14 Takes Shape: What Investors Should Watch

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. Axsome Therapeutics, Inc. is running a...

17d ago

AXSM

Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating

Axsome Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

1M ago

AXSM

Axsome Therapeutics price target raised to $304 from $302 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $304 from $302...

1M ago

AXSM

Blair adds American Express, Oracle to Conviction List in monthly update

William Blair analysts, in their monthly update, added the following stocks to its Analyst Conviction List: American Express...

1M ago

0HKF FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest share price was $103.40 and its highest was $263.93 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $11.22B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Aug 10, 2026 which is today.

How were Axsome Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.89.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 51,459,766 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in GB:0HKF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

19.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Axsome Therapeutics (0HKF) Earnings & Revenues

Historic Earnings Reports

0HKF Company Deck

0HKF Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.View all GB:0HKF earnings summaries

0HKF Stock 12 Month Forecast

Average Price Target

$300.38

▲(25.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"102":"$102","381":"$381","171.75":"$171.8","241.5":"$241.5","311.25":"$311.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":380,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$380.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300.375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$300.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$255.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[102,171.75,241.5,311.25,381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.62,231.03384615384616,243.4476923076923,255.86153846153846,268.2753846153846,280.6892307692308,293.1030769230769,305.5169230769231,317.9307692307692,330.3446153846154,342.7584615384615,355.1723076923077,367.5861538461538,{"y":380,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.62,224.90884615384616,231.1976923076923,237.48653846153846,243.7753846153846,250.06423076923076,256.3530769230769,262.6419230769231,268.9307692307692,275.2196153846154,281.5084615384615,287.7973076923077,294.0861538461538,{"y":300.375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.62,221.41846153846154,224.21692307692308,227.01538461538462,229.81384615384616,232.6123076923077,235.41076923076923,238.20923076923077,241.0076923076923,243.80615384615385,246.60461538461539,249.40307692307692,252.20153846153846,{"y":255,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.061,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.113,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.935,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.141,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.057,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.635,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.31,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >